Pharmacovigilance methods in public health programmes: the example of miltefosine and visceral leishmaniasis.

[1]  Rajendra Prasad,et al.  Adverse drug reactions to antiretroviral therapy (ART): an experience of spontaneous reporting and intensive monitoring from ART centre in India , 2010, Pharmacoepidemiology and drug safety.

[2]  J. Sejvar,et al.  Vaccines and Guillain-Barré Syndrome , 2009, Drug safety.

[3]  P. Rosenthal,et al.  Monitoring antimalarial safety and tolerability in clinical trials: A case study from Uganda , 2008, Malaria Journal.

[4]  A. Joshi,et al.  Can visceral leishmaniasis be eliminated from Asia? , 2008, Journal of vector borne diseases.

[5]  D. Durrheim,et al.  Malaria deaths as sentinel events to monitor healthcare delivery and antimalarial drug safety , 2007, Tropical medicine & international health : TM & IH.

[6]  J. Engel,et al.  Development of miltefosine as an oral treatment for leishmaniasis. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[7]  S. Sundar,et al.  Visceral leishmaniasis - current therapeutic modalities. , 2006, The Indian journal of medical research.

[8]  N. Kshirsagar.  The Pharmacovigilance System in India , 2005, Drug safety.

[9]  Shyam Sundar,et al.  Oral miltefosine for Indian visceral leishmaniasis. , 2002, The New England journal of medicine.

[10]  M. Rai,et al.  Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Sundar,et al.  Immunochromatographic strip-test detection of anti-K39 antibody in Indian visceral leishmaniasis , 2002, Annals of tropical medicine and parasitology.

[12]  N. Gogtay,et al.  Adverse drug reaction (ADR) monitoring in India and the postal survey as a useful tool for ADR detection , 2000, Pharmacoepidemiology and drug safety.

[13]  Rolf Lefering,et al.  Probability of adverse events that have not yet occurred: a statistical reminder , 1995, BMJ.

[14]  R. Jeffery,et al.  Pharmaceuticals and health policy: an Indian example. , 1988, Social science & medicine.